Nasdaq’s Post

Amanda Malone at Eupraxia Pharmaceuticals Inc. is presenting the data from Phase 2 #osteoarthritis trial results. It is great to see the success of EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension) in this study and discuss how this product can impact patient pain and function at #ACR23, with Dr. Olga Kubassova, Mikael Boesen and Asger Bihlet. #rheumatology #osteoarthritis #success #pain #steroids

If you missed our "Targeted Pain Treatment" webinar, please enjoy the recording of that discussion. Special thanks to our guest speakers Stephanie G. Vanterpool MD, MBA, FASA and Scott Chappell of Galt Pharmaceuticals. #targetedpaintreatment #painmanagement https://lnkd.in/ejy4dTXt

Interesting insights from the Crumdale Partners conference. What’s your strategy to control high cost specialty medications? 2023 NEW APPROVALS The FDA approved a milestone 67 New drugs in 2023 predominately orphan & breakthrough therapies. 55 specialty & 12 traditional. - Zepbound (Weight Loss) - Bimzlex (Psoriasis) - Omvoh, Velsipity (UC) - Zurzuvae (Post-partum dep.) - Exxua (Depression) - Opill (First OTC O/C) - 5 Unique Biosimilars (9 Humira) 2024-2025 DRUG PIPELINE - fenebrutinib, tolebrutinib (MS) - ansofaxine (Depression) - donanemab (Alzheimer's) - semaglutide-oral, retatrutide - orforglipron (Weight Loss)

In recent years, the field of pain management has witnessed a remarkable transformation, marked by groundbreaking innovations that promise to revolutionize the way we address and alleviate pain. From cutting-edge pharmaceutical developments and minimally invasive procedures to advanced neuromodulation techniques and integrative therapies, a new era of pain relief has dawned. https://lnkd.in/dk7ERVQj

Surrozen has decided to halt further development of its inflammatory bowel disease (IBD) therapy, SZN-1326. Challenges in determining a safe and effective dosage, along with the competitive landscape in the pharmaceutical market, have led to this strategic shift. This decision marks a significant development for Surrozen and its efforts to address IBD. #Surrozen #ibd #drugdevelopment #therapy #healthcare #lifesciences

Here's the replay of this week's Bloomberg Intelligence Biopharma call that takes place every Thursday at 10AM New York time. Please contact me if you'd like to be added to our email list for reminders about this call and other events. I discuss BridgeBio's topline amyloidosis data and possible readthroughs for Alnylam Pharmaceuticals as well as the implications of CMS revisiting its restrictive stance on amyloid beta PET scans for Biogen-Eisai US as the partners roll out Leqembi. Jean Rivera Irizarry, Ph.D. dissects new Phase 3 Alzheimer's data from Eli Lilly and Company and A.H. Van Kirk shares her latest analysis on Sangamo Therapeutics, Inc., Acadia Pharmaceuticals Inc., Teva Pharmaceuticals and others. Grace Guo, CFA rounds out the call with next week’s catalysts. https://lnkd.in/en3Yp-gq #bloombergintelligence #bloomberg #biotech #biopharmaceuticals #pharma #alzheimers #alzheimersdisease #amyloidosis #cms #cardiomyopathy

Our department's groundbreaking research on 'A Comparative Study of Metformin versus Metformin + Myo-Inositol Combination and Effect of Lifestyle Intervention in Polycystic Ovarian Disease Patients' has been published in the International Journal of Pharmacy and Pharmaceutical Research. Thrilled to contribute to advancements in PCOS management. #Research #PCOS #Healthcare"

#NewDrug Alert- The second Stelara biosimilar, Selarsdi, was approved on 4/16/24. But now we still wait! Anticipating Wezlana, approved 10/31/23 to launch 1/1/25, as interchangeable. Selarsdi and up to 2 others to follow at the end of February 2025. 🤞 for a quicker uptake than what we saw with Humira biosimilars! Some PBMs are already taking about the aggressive stance they plan on taking earlier with their lessons learned. Hopefully this translates to more savings quicker. #Pharmacists #Pharmacybenefits #biosimilars #PBM https://lnkd.in/g2uUir6Z

#DYK that 1 out of 2 #lupus patients will develop lupus nephritis? For more information on #lupusnephiritis, check out the event we hosted yesterday in collaboration with Aurinia Pharmaceuticals. #LAM24 #LupusAwarenessMonth